CN101454462A - 与药物不良反应相关的hla等位基因及其检测方法 - Google Patents

与药物不良反应相关的hla等位基因及其检测方法 Download PDF

Info

Publication number
CN101454462A
CN101454462A CNA2007800170212A CN200780017021A CN101454462A CN 101454462 A CN101454462 A CN 101454462A CN A2007800170212 A CNA2007800170212 A CN A2007800170212A CN 200780017021 A CN200780017021 A CN 200780017021A CN 101454462 A CN101454462 A CN 101454462A
Authority
CN
China
Prior art keywords
hla
substituted
patient
heterocyclic radical
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800170212A
Other languages
English (en)
Chinese (zh)
Inventor
陈垣崇
洪舜郁
沈志隆
张绮芬
林心郁
陈维萱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiji Biomedical Co ltd
Academia Sinica
Original Assignee
Shiji Biomedical Co ltd
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101454462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shiji Biomedical Co ltd, Academia Sinica filed Critical Shiji Biomedical Co ltd
Publication of CN101454462A publication Critical patent/CN101454462A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2007800170212A 2006-05-11 2007-05-11 与药物不良反应相关的hla等位基因及其检测方法 Pending CN101454462A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
US60/800,121 2006-05-11

Publications (1)

Publication Number Publication Date
CN101454462A true CN101454462A (zh) 2009-06-10

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800170212A Pending CN101454462A (zh) 2006-05-11 2007-05-11 与药物不良反应相关的hla等位基因及其检测方法

Country Status (17)

Country Link
US (2) US7943309B2 (enExample)
EP (1) EP2016198B1 (enExample)
JP (1) JP2009536828A (enExample)
KR (1) KR101450348B1 (enExample)
CN (1) CN101454462A (enExample)
AU (1) AU2007249225B2 (enExample)
BR (1) BRPI0710436A8 (enExample)
CA (1) CA2651954C (enExample)
DK (1) DK2016198T3 (enExample)
ES (1) ES2422735T3 (enExample)
IL (1) IL194900A (enExample)
MY (1) MY150648A (enExample)
NZ (2) NZ597628A (enExample)
PL (1) PL2016198T3 (enExample)
PT (1) PT2016198E (enExample)
TW (1) TWI335937B (enExample)
WO (1) WO2007134235A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
CN102660635A (zh) * 2012-01-14 2012-09-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN102918396A (zh) * 2010-04-12 2013-02-06 中央研究院 利用人类白血球抗原(hla)筛检预测药物不良反应的方法
CN104017898A (zh) * 2014-06-25 2014-09-03 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781A (zh) * 2014-09-26 2014-12-24 陕西佰美基因股份有限公司 一种检测HLA-B*5801等位基因的TaqMan探针实时荧光PCR方法
CN105722999A (zh) * 2013-09-17 2016-06-29 新加坡科技研究局 检测遗传变体的方法
CN106119362A (zh) * 2016-06-30 2016-11-16 江苏伟禾生物科技有限公司 一种用于检测hla‑b*1502等位基因的引物组及试剂盒
CN108929902A (zh) * 2018-07-28 2018-12-04 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
WO2020223867A1 (zh) * 2019-05-06 2020-11-12 长庚医疗财团法人林口长庚纪念医院 评估疾病调节抗风湿药物引发严重皮肤药物不良反应风险的方法、其检测试剂盒及其用途
CN114262736A (zh) * 2021-05-28 2022-04-01 上海康黎诊断技术有限公司 一种用于检测人hla-b*15：02基因突变的引物探针组合及其试剂盒，以及方法
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
WO2012174723A1 (en) * 2011-06-23 2012-12-27 Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung Risk assessment for phenytoin-induced adverse drug reactions
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5883238A (en) * 1993-03-18 1999-03-16 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
US5550039A (en) 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
BRPI0407569A (pt) * 2003-02-17 2006-02-14 Novartis Ag uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918396A (zh) * 2010-04-12 2013-02-06 中央研究院 利用人类白血球抗原(hla)筛检预测药物不良反应的方法
CN102918396B (zh) * 2010-04-12 2016-05-11 中央研究院 利用人类白血球抗原(hla)筛检预测药物不良反应的方法
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
CN102660635A (zh) * 2012-01-14 2012-09-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN105722999A (zh) * 2013-09-17 2016-06-29 新加坡科技研究局 检测遗传变体的方法
CN104017898A (zh) * 2014-06-25 2014-09-03 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781A (zh) * 2014-09-26 2014-12-24 陕西佰美基因股份有限公司 一种检测HLA-B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362A (zh) * 2016-06-30 2016-11-16 江苏伟禾生物科技有限公司 一种用于检测hla‑b*1502等位基因的引物组及试剂盒
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902A (zh) * 2018-07-28 2018-12-04 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
WO2020223867A1 (zh) * 2019-05-06 2020-11-12 长庚医疗财团法人林口长庚纪念医院 评估疾病调节抗风湿药物引发严重皮肤药物不良反应风险的方法、其检测试剂盒及其用途
CN112513294A (zh) * 2019-05-06 2021-03-16 长庚医疗财团法人林口长庚纪念医院 评估疾病调节抗风湿药物引发严重皮肤药物不良反应风险的方法、其检测试剂盒及其用途
KR20210149135A (ko) * 2019-05-06 2021-12-08 창 궁 메모리얼 하스피털, 린커우 질환-변형 항류마티스 약물에 의해 유발되는 중증 피부 약물 이상 반응이 발생할 위험을 평가하는 방법, 이의 검출 키트 및 이의 용도
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
KR102800941B1 (ko) * 2019-05-06 2025-04-29 창 궁 메모리얼 하스피털, 린커우 질환-변형 항류마티스 약물에 의해 유발되는 중증 피부 약물 이상 반응이 발생할 위험을 평가하는 방법, 이의 검출 키트 및 이의 용도
CN114262736A (zh) * 2021-05-28 2022-04-01 上海康黎诊断技术有限公司 一种用于检测人hla-b*15：02基因突变的引物探针组合及其试剂盒，以及方法

Also Published As

Publication number Publication date
MY150648A (en) 2014-02-14
ES2422735T3 (es) 2013-09-13
AU2007249225A1 (en) 2007-11-22
WO2007134235A3 (en) 2008-01-17
CA2651954A1 (en) 2007-11-22
EP2016198B1 (en) 2013-05-01
DK2016198T3 (en) 2013-07-15
KR20090031671A (ko) 2009-03-27
IL194900A (en) 2013-02-28
BRPI0710436A8 (pt) 2018-06-26
AU2007249225B2 (en) 2013-06-27
US20080145846A1 (en) 2008-06-19
WO2007134235A2 (en) 2007-11-22
KR101450348B1 (ko) 2014-10-14
TWI335937B (en) 2011-01-11
CA2651954C (en) 2014-02-25
IL194900A0 (en) 2009-08-03
US20110212439A1 (en) 2011-09-01
NZ572259A (en) 2012-03-30
EP2016198A2 (en) 2009-01-21
PL2016198T3 (pl) 2013-12-31
JP2009536828A (ja) 2009-10-22
PT2016198E (pt) 2013-07-29
BRPI0710436A2 (pt) 2012-10-09
TW200844238A (en) 2008-11-16
US8142999B2 (en) 2012-03-27
NZ597628A (en) 2013-07-26
EP2016198A4 (en) 2010-07-21
US7943309B2 (en) 2011-05-17

Similar Documents

Publication Publication Date Title
CN101454462A (zh) 与药物不良反应相关的hla等位基因及其检测方法
ES2347150T3 (es) Evaluacion de riesgo de reacciones adversas a farmacos.
Noble et al. The HLA class IA locus affects susceptibility to type 1 diabetes
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
US20160102367A1 (en) Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral t-cell lymphomas
BRPI0714158A2 (pt) mÉtodos para inibir a proliferaÇço de cÉlula de tumor de cÉlula b, para tratar um paciente tendo um tumor, para tratar um paciente tendo uma molÉcula de transduÇço de sinalizaÇço taki desregulada, para inibir o crescimento de um tumor sàlido, para selecionar um paciente tendo um tumor que É sustetÍvel a tratamento com um inibidor taki, para inibir a proliferaÇço de uma leucemia de cÉlula t e linfomas de cÉlula-t, e para selecionar um mamÍfero tendo ou mÉtodos para inibir a proliferaÇço de cÉlula de tumor de cÉlula b, para tratar um paciente tendo um tumor, para tratar um paciente tendo uma molÉcula de transduÇço de sinalizaÇço tak1 desregulada, para inibir o crescimento de um tumor sàlido, para selecionar um paciente tendo um tumor que É suscetÍvel a tratamento com um inibidor tak1, para inibir a proliferaÇço de uma leucemia de cÉlula t e linfomas de cÉlula-t, e para selecionar um mamÍfero tendo ou suspeito de ter um tumor para tratamento com um medicamento inibidor tak1
TW201713776A (zh) Ｈｌａ－ｂ＊１５：０２中的單一核苷酸多型性及其用途
CN106868163B (zh) 基于flt3和nat2基因的与抗结核药物肝毒性反应相关的snp标志物、试剂盒及应用
CN101240321A (zh) 一种检测毒物代谢遗传风险的试剂盒
CN106868162B (zh) 基于ppp2r2b和nat2基因的与抗结核药物肝毒性反应相关的snp标志物、试剂盒及应用
CN106868161B (zh) 基于blnk和nat2基因的与抗结核药物肝毒性反应相关的snp标志物、试剂盒及应用
JP2005503152A (ja) 薬剤過敏症反応についてのスクリーニング方法
HK1134325A (en) Hla alleles associated with adverse drug reactions and methods for detecting such
Rossiter et al. Clinical applications of the polymerase chain reaction
CN107058527B (zh) 基于kcne3和nat2基因的与抗结核药物肝毒性反应相关的snp标志物、试剂盒及应用
AU2013219191A1 (en) Hla alleles associated with adverse drug reactions and methods for detecting such
PL226331B1 (pl) Sposób wykrywania genetycznie uwarunkowanej wysokiej predyspozycji do raka piersi oraz zastosowanie mutacji skracających białko CHEK2
Park High-throughput genetic association study on candidate genes for nonsyndromic oral clefts
Shirts Interaction between herpesviruses and genetic variation in schizophrenia pathogenesis: A candidate gene approach
JPWO2004078963A1 (ja) ステロイド応答性の検査方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1134325

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090610

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1134325

Country of ref document: HK